Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

NCT04294641 ·Status: COMPLETED ·Phase: PHASE2

Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants

NCT00775632 ·Status: COMPLETED ·Phase: PHASE2

Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02669251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases

NCT06480630 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD)

NCT05276076 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

NCT03657160 ·Status: COMPLETED ·Phase: PHASE3

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

NCT00611351 ·Status: COMPLETED ·Phase: PHASE2

Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant

NCT03774082 ·Status: COMPLETED ·Phase: PHASE2

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease

NCT01713400 ·Status: COMPLETED ·Phase: PHASE2

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

NCT01701986 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis

NCT05515029 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT

NCT00506922 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

NCT00410982 ·Status: COMPLETED ·Phase: PHASE1

A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

NCT06681922 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD

NCT02461134 ·Status: TERMINATED ·Phase: PHASE2

Autologous Transplantation for Chronic Myelogenous Leukemia

NCT01003054 ·Status: COMPLETED ·Phase: PHASE2

Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

NCT00054340 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT

NCT02876679 ·Status: COMPLETED ·Phase: PHASE2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424 ·Status: RECRUITING ·Phase: PHASE2

2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II

NCT03941769 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement

NCT06066840 ·Status: RECRUITING ·Phase: PHASE4

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

NCT02793544 ·Status: COMPLETED ·Phase: PHASE2

Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

NCT00369226 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide

NCT04622956 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease

NCT01001780 ·Status: WITHDRAWN ·Phase: PHASE2